<DOC>
	<DOCNO>NCT02758509</DOCNO>
	<brief_summary>Hepatitis C virus ( HCV ) chronic infection affect 200 million people worldwide . HCV antiviral treatment evolve rapidly since 2011 . The use pegylated interferon ( PEG-INF ) ribavirin ( RBV ) suppose high serious adverse event ( SAEs ) low efficacy , especially patient cirrhosis . The introduction 1st generation protease inhibitor ( PIs ) genotype-1 ( GT1 ) HCV , boceprevir ( BOC ) telaprevir ( TVR ) , improved efficacy increase SAEs . Currently , interferon-free direct-acting antiviral ( IF-DAAs ) achieve great effectiveness minimum SAEs . However , study evaluate efficacy safety DAAs cirrhotic patient limited real clinical practice . The aim study evaluate HCV-cirrhotic patient efficacy safety 3 treatment strategy ( PEG-IFN/RBV , PEG-IFN/RBV/PIs , IF-DAAs ) routine practice accord European guideline 2010 2015 . The secondary aim evaluate impact sustain virological response gastroesophageal varix ( GOV ) .</brief_summary>
	<brief_title>Impact Antiviral Therapy Gastroesophageal Varices .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Age ≥ 18 year . Signed informed consent . Chronic hepatitis C ( antiHCV antibody detectable HCVRNA ) . Liver cirrhosis ( transient elastography ≥ 14 kPa ) . Baseline upper gastrointestinal endoscopy ass gastroesophageal varix Negative provide sign informed consent . Negative perform gastrointestinal endoscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>